BiDil: from another vantage point.

Abstract excerpt

In a recent Health Affairs Web Exclusive, Pamela Sankar and Jonathan Kahn argue against the Food and Drug Administration's approval of BiDil as a new drug for the treatment of heart failure in African Americans. Their paper questions the existence of disparities between African American and other heart-failure patients and the motivations of BiDil's developers and manufacturer. The disparities are confirmed and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Black or African American
• Share to Drug Approval
• Share to Drug Combinations